In this episode of Healthcare Happy Hour, David Saltzman interviews Lena Chaihorsky, co-founder and senior vice president of Payer Innovation at Alva10, discussing the concept of precision medicine and its implications for healthcare delivery. They explore the importance of pharmacogenomics, the role of brokers in implementing precision medicine, and the need for education among employers regarding these innovative healthcare solutions. Lena emphasizes the significance of drug efficacy and the financial implications of non-optimized medications, while also highlighting real-world applications and future directions for the NABIP's Precision Medicine Task Force.
Takeaways
- Precision medicine uses individual patient data for healthcare decisions.
- Pharmacogenomics can predict drug responses based on DNA.
- 20% of Americans on certain drugs need pharmacogenomic testing.
- Non-optimized medications lead to significant healthcare costs.
- Brokers play a crucial role in delivering precision medicine.
- Education on precision medicine is essential for employers.
- Case studies show cost reductions with pharmacogenomic testing.
- Efficacy of drugs should be prioritized over costs.
- Precision medicine can reduce diagnostic odysseys for patients.
- The task force aims to create certification programs for brokers.
Do you have a topic you’d like us to cover or a question you would like us to address in an upcoming podcast?
If so, send us an email here.